The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte SUZANNE DE LA MONTE and JACK R. WANDS
__________
Appeal No. 2006-02991
Application No. 09/964,412
__________
HEARD: March 9, 2006
__________
Before SCHEINER, GRIMES and GREEN, Administrative Patent Judges.
SCHEINER, Administrative Patent Judge.
DECISION ON APPEAL
This appeal involves a method of treating dementia by administering an
antisense oligonucleotide complementary to AD7c-NTP, a neural thread protein
said to be expressed at high levels in the brains of Alzheimer’s disease patients.
The examiner has rejected the claims as lacking enablement. We have
jurisdiction under 35 U.S.C. § 134. We will reverse this rejection.
BACKGROUND
Alzheimer’s disease “is the most prevalent neurodegenerative disease
and the most common cause of dementia in the Western hemisphere.”
1 This appeal is related to an appeal in application serial no. 09/964,667 (appeal no. 2006-0275).
We have considered the two appeals together.
Page: 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007